收费全文 | 6378篇 |
免费 | 539篇 |
国内免费 | 25篇 |
耳鼻咽喉 | 44篇 |
儿科学 | 234篇 |
妇产科学 | 145篇 |
基础医学 | 853篇 |
口腔科学 | 134篇 |
临床医学 | 577篇 |
内科学 | 1580篇 |
皮肤病学 | 163篇 |
神经病学 | 559篇 |
特种医学 | 310篇 |
外科学 | 941篇 |
综合类 | 95篇 |
预防医学 | 472篇 |
眼科学 | 132篇 |
药学 | 350篇 |
中国医学 | 17篇 |
肿瘤学 | 336篇 |
2023年 | 43篇 |
2022年 | 77篇 |
2021年 | 170篇 |
2020年 | 142篇 |
2019年 | 189篇 |
2018年 | 213篇 |
2017年 | 188篇 |
2016年 | 177篇 |
2015年 | 186篇 |
2014年 | 215篇 |
2013年 | 278篇 |
2012年 | 370篇 |
2011年 | 339篇 |
2010年 | 228篇 |
2009年 | 227篇 |
2008年 | 249篇 |
2007年 | 298篇 |
2006年 | 286篇 |
2005年 | 313篇 |
2004年 | 207篇 |
2003年 | 211篇 |
2002年 | 161篇 |
2001年 | 151篇 |
2000年 | 146篇 |
1999年 | 141篇 |
1998年 | 88篇 |
1997年 | 77篇 |
1996年 | 78篇 |
1995年 | 50篇 |
1994年 | 66篇 |
1993年 | 55篇 |
1992年 | 139篇 |
1991年 | 122篇 |
1990年 | 117篇 |
1989年 | 117篇 |
1988年 | 100篇 |
1987年 | 85篇 |
1986年 | 80篇 |
1985年 | 61篇 |
1984年 | 43篇 |
1983年 | 52篇 |
1982年 | 38篇 |
1981年 | 19篇 |
1980年 | 28篇 |
1979年 | 35篇 |
1978年 | 34篇 |
1977年 | 31篇 |
1974年 | 24篇 |
1972年 | 19篇 |
1966年 | 19篇 |
Objective
This study proposes three indicators of, and assesses the disparities and trends in, the risk of HIV infection progression among people living with diagnosed HIV infection in the United States.Methods
Using data reported to national HIV surveillance through June 2012, we calculated the AIDS diagnosis hazard, HIV (including AIDS) death hazard, and AIDS death hazard for people living with diagnosed HIV infection for each calendar year from 1997 to 2010. We also calculated a stratified hazard in 2010 by age, race/ethnicity, mode of transmission, region of residence at diagnosis, and year of diagnosis.Results
The risk of HIV infection progression among people living with diagnosed HIV infection decreased significantly from 1997 to 2010. The risks of progression to AIDS and death in 2010 were higher among African Americans and people of multiple races, males exposed through injection drug use (IDU) or heterosexual contact, females exposed through IDU, people residing in the South at diagnosis, and people diagnosed in 2009 compared with white individuals, men who have sex with men, females with infection attributed to heterosexual contact, those residing in the Northeast, and those diagnosed in previous years, respectively. People aged 15–29 years had the highest AIDS diagnosis hazard in 2010.Conclusion
Continued efforts are needed to ensure early HIV diagnosis as well as initial linkage to and continued engagement in HIV medical care among all people living with HIV. Targeted interventions are needed to improve health-care and supportive services for those with worse health outcomes.In the United States, the number of people aged 13 years and older living with human immunodeficiency virus (HIV) infection was estimated to be more than 1.1 million as of December 2010, a 9% increase from 2006.1 For people living with HIV, increasing their access to care and eliminating disparities are primary goals of the National HIV/AIDS Strategy (NHAS) and the Healthy People 2020 objectives.2,3 Assuring that all people with HIV are diagnosed early, promptly linked to care, retained in care, and offered antiretroviral treatment is essential to achieve the ultimate goal of the continuum of care,4 leading to viral suppression, improved health, survival, and prevention of HIV transmission.Several studies have used national HIV surveillance data to examine the disparities and determinants of progression to acquired immunodeficiency syndrome (AIDS; i.e., stage 3 HIV infection5) and death after HIV diagnosis. These studies have focused on individuals diagnosed in a certain time period and have examined the differences in time from HIV diagnoses to AIDS and death (i.e., the number of months/years from HIV diagnosis to AIDS or death) using survival analyses, including Kaplan-Meier survival curves, the Cox proportional hazard model, or the standardized relative risk.6–8 However, previous studies have not assessed the risks of progression to AIDS and death among all people living with HIV, and have not reported the trends in these outcomes.To fill this gap, we propose in this study three cross-sectional indicators to estimate the risks of progression to AIDS and death in a calendar year after HIV diagnoses among people living with diagnosed HIV infection, regardless of their time of diagnosis (i.e., the year when an HIV infection was first diagnosed). The results allow for an annual assessment of the risks of HIV infection progression and can be used to monitor the trends in these outcomes among people living with HIV.Specifically, this study (1) examined the disparities in the risk of progression to AIDS in 2010 among people living with diagnosed HIV (not AIDS) infection at year-end 2009 (AIDS diagnosis hazard), the risk of death in 2010 among those living with diagnosed HIV (including AIDS) infection at year-end 2009 (HIV death hazard), and the risk of death in 2010 among individuals living with AIDS at year-end 2009 (AIDS death hazard); and (2) assessed the trends in the risks of HIV infection progression among people living with diagnosed HIV infection from 1997 to 2010 using the three indicators. 相似文献Methods: Single center, retrospective cohort study including patients with hypertriglyceridemia between January 2007 and December 2016. Main measures included frequency of pancreatitis, choice of lipid-lowering therapy, and clinical comparisons of diet, oral lipid-lowering agents, IV insulin, and apheresis.
Results: Initial serum triglyceride level and disease acuity was higher among patients in insulin and apheresis groups. Neither triglyceride level, Charlson comorbidity index, age, BISAP score, nor initial CRP predicted use of IV insulin versus apheresis. Prevalence of pancreatitis increased with higher triglyceride level, reaching 48% with triglycerides >2000 md/dL (p < 0.001). There was a significant decrease in serum triglycerides at each time interval (p < 0.05) in patients treated with IV insulin and apheresis, but no difference in clearance rate between the two. Length of stay did not differ between IV insulin and apheresis.
Conclusion: The presence of pancreatitis, hyperglycemia, and hypertriglyceridemia severity influenced selection of therapies like IV insulin and apheresis. We found no superiority of either IV insulin or apheresis in the treatment of severe hypertriglyceridemia among patients hospitalized for pancreatitis. 相似文献